A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Phase 2 Recruiting 110 enrolled Nanjing Leads Biolabs Co.,Ltd Peking University Cancer Hospital & Institute · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.

Timeline

Start: 2026-02-26
Primary completion: 2028-12-26
Completion: 2028-12-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LBL-024	Unknown	—	Intravenous
Comparator	Tislelizumab	Monoclonal antibody	—	Intravenous
Background	Capecitabine	Small molecule	—	Oral
Background	Cisplatin	Other / unclassified	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous
Background	fluorouracil	Small molecule	—	Intravenous

Indications

No indication recorded.